anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This study aims to observe if there is a correlation between increasing one's physical activity levels via a bodyweight exercise program and a change in bone density, cognition, and quality of live for patients diagnosed with Multiple Sclerosis. The subjects enrolled in this study will perform a six week training cycle which includes one session per week located at Holy Name Medical Center (physical therapy department) as well as one session per week performed at the subject's home (video guide will be distributed). The training sessions should take approximately 30 minutes and include 3 sets of 10 repetitions for each of the individual exercises. There are five unchanging exercises that will be performed at each training session which include: wall push ups, chair squats, chair dips, step ups, and calf raises. Each subject will be required to perform both training sessions per week for six weeks. The following two weeks are set aside for make up dates for any missed training sessions if needed. During this six to eight week training (treatment) phase, one of the study investigators will remain in contact with the subjects of the study as to ensure commitment of at home training sessions. Prior to the training phase of this study, each subject will have a bone density DEXA scan performed and must complete SDMT (symbol digit modalities test) and MSIS-29 (multiple sclerosis impact scale) evaluations. Both the SDMT and MSIS-29 evaluations with be filled out again within two weeks of the completion of the training phase. 8 weeks after completion of the training phase of the study, each subject will return for a second bone density DEXA scan as well as complete both the SDMT and MSIS-29 evaluations for a third time. The duration of the study will fall between 14 and 16 weeks for any given participant depending on if the additional two weeks are needed to complete the training (treatment) phase. Previous research in this area have supported that bodyweight exercise had a positive impact on fatigue, muscle strength, and balance. Improvements in quality of life as well as cognition have also been documented by MS patients after performing exercise regimen. Because of the positive effects of exercise on patients with MS, the investigators in this study investigated the effects of weight-based training on bone density, cognition, depression, and quality of life in MS patients.
NEW MATERIAL:A compound shown by the formula I (X1-X3 are H, or 2- 21C polyfluoroacyl; with the proviso that at least one of them is polyfluoroacyl). EXAMPLE:2,6-Di(perfluorooctanoyl)ascorbic acid. USE:An antiphage agent, an antimicrobial agent, an antioxidant, etc. Showing improved stability than well-known L-ascorbic acid derivative. PREPARATION:For example, L-ascorbic acid is reacted with a carboxylic acid shown by the formula II (R1 is 1-20C polyfluoroalkyl) in conc. sulfuric acid at room temperature to give a 6-ester derivative shown by the formula I . Or, an acid chloride shown by the formula II or an acid anhydride is reacted with L-ascorbic acid in the presence of a base at room temperature or under cooling with ice to give the 2,6-diester derivative shown by the formula I or a 2,5,6-triester derivative. Further, 5,6-isopropyliden-ascorbic acid is reacted with the acid chloride shown by the formula II in the presence of a base to give the 2-ester derivative shown by the formula I .
BACKGROUND: We describe the clinical course of children with IgA nephropathy (IgAN), diagnosed before and after the emergence of COVID-19. We hypothesized that COVID-19 vaccination and/or infection resulted in more children with IgAN to present clinically.
METHODS: We conducted a retrospective cohort study of children with IgAN diagnosed on kidney biopsy from 2014-2020 (Period 1) and 2021-2022 (Period 2). Baseline characteristics, clinical presentation, investigations and treatments were compared between patients diagnosed in Period 1 and Period 2, as well as between patients with and without chronic changes on kidney biopsy. Continuous variables were compared using the Wilcoxon rank sum test. Categorical variables were compared using χ2 or Fisher exact tests.
RESULTS: Nineteen children with IgAN were diagnosed by kidney biopsy, with 10 during Period 1 and 9 patients during Period 2 (an average of 1-2 patients/year and 4-5 patients/year in Periods 1 and 2, respectively). The most common indication for kidney biopsy is proteinuria with urine protein/creatinine ratio 1.4 (interquartile range [IQR] 1.2-9.0) vs. 0.8 (IQR 0.6-1.5) g/g (p = 0.064) at time of kidney biopsy for patients in Period 1 and 2, respectively. Clinical course was similar in both periods. No patient required acute or chronic kidney replacement therapy.
CONCLUSIONS: The rate of diagnosing children with IgAN was higher since the emergence of COVID-19, suggesting that COVID-19 may trigger an immune response responsible for IgAN, similar to other mucosal infections.
Abiraterone acetate may cause hypertension, hypokalemia, and fluid retention as a consequence of increased mineralocorticoid levels resulting from CYP17 inhibition [see Clinical Pharmacology (12.1)]. Monitor patients for hypertension, hypokalemia, and fluid retention at least once a month. Control hypertension and correct hypokalemia before and during treatment with abiraterone acetate. 

In the combined data from 4 placebo-controlled trials using prednisone 5 mg twice daily in combination with 1,000 mg abiraterone acetate daily, grades 3 to 4 hypokalemia were detected in 4% of patients on the abiraterone acetate arm and 2% of patients on the placebo arm. Grades 3 to 4 hypertension were observed in 2% of patients each arm and grades 3 to 4 fluid retention in 1% of patients each arm. 

In LATITUDE (a randomized placebo-controlled, multicenter clinical trial), which used prednisone 5 mg daily in combination with 1,000 mg abiraterone acetate daily, grades 3-4 hypokalemia were detected in 10% of patients on the abiraterone acetate arm and 1% of patients on the placebo arm, grades 3-4 hypertension were observed in 20% of patients abiraterone acetate arm and 10% of patients on the placebo arm. Grades 3-4 fluid retention occurred in 1% of patients each arm [see Adverse Reactions (6)].

Closely monitor patients whose underlying medical conditions might be compromised by increases in blood pressure, hypokalemia or fluid retention, such as those with heart failure, recent myocardial infarction, cardiovascular disease, or ventricular arrhythmia. In postmarketing experience, QT prolongation and Torsades de Pointes have been observed in patients who develop hypokalemia while taking abiraterone acetate.

The safety of abiraterone acetate in patients with left ventricular ejection fraction ˂ 50% or New York Heart Association (NYHA) Class III or IV heart failure (in COU-AA-301) or NYHA Class II to IV heart failure (in COU-AA-302 and LATITUDE) has not been established because these patients were excluded from these randomized clinical trials [see Clinical Studies (14)].
The present invention relates to a cosmetic containing a trace amount of lignin degradation substances and a preparation method thereof. The cosmetic is composed of 0.05 to 0.112 Wt. % of lignin degradation substances, 25 to 30 Wt. % of base materials, 1 to 2 Wt. % of emulsifying agents and an equilibrium amount of water, wherein the lignin degradation substances are extracted from black liquor for making paper. The present invention is a cosmetic which has the effect of beautifying faces, eliminates skin melanin, acne, chloasma, etc., and has no side effect.
Kidney transplants group is a kidney transplant subjects population 3 months ago. Exosome analysis will be perform in urine sample collected at 3 months.
The invention relates to an external plaster for treating bone injuries. The raw materials of the external plaster involve the following Chinese medicinal materials by weight: 100-200g of poplar buds, 150-250g of elm barks, 50-150g of calcined oxhorns, 50-100g of cartialgenous, 100g of Achyranthes, 100g of monkshood, 100g of Radix Aconiti kusnezoffii, 150g of radix clematidis, 100-150g of pseudo-ginseng, 100g of the roots of fangji and 150g of rhizoma corydalis. The preparation method of the external plaster comprises the steps of: crushing the medicinal materials into fine powder, sieving the powder with an 80-mesh sieve and mixing the powder uniformly, then putting the powder into a pot, adding 2000ml of boiled water at 80DEG C, stirring them evenly and soaking them for 30min, decocting the mixture with slow fire and adding 500ml of edible vinegar simultaneously, and carrying out decoction for 60min till obtaining a black jelly pasty ointment for stand-by use. Compared with the prior art, the plaster provided by the invention is good for patients with bone injuries, the treatment period is shortened and the cure rate is high, so that the plaster can substitute the therapies of western medicine surgeries and operations employing steel nails and iron hooks. Besides, the plaster does not cause sequela, or require amputation, and can prevent infection. According to years of clinical practice, and diagnosis and observation of tens of thousands of patients, the plaster has a total effective rate of 97.76% and a cure rate of 93% on bone fractures, and a total effective rate of 93% and a cure rate of 81% for treatment of lumbar disc herniation.
The development of an ideal therapy to immunosuppress patients with Behcet's disease, a cause of endogenous uveitis and a major cause of acquired blindness in adults, is an important research goal. Corticosteroids remain the mainstay of therapy for intraocular inflammation; however, many patients are intolerant or resistant to corticosteroid therapy. Although the etiology of Behcet's disease is unknown, evidence suggests that an interleukin-2 receptor bearing auto-aggressive cells may play an important role in this disorder. Zenapax, a humanized anti-TAC (T-cell activated antigen) monoclonal antibody (HAT), has been utilized in Protocol # 96-EI-0096, a pilot Phase I/II study, to evaluate Zenapax administration in the treatment of patients with endogenous sight-threatening uveitis. Long-term results demonstrate a positive therapeutic trend in this trial. We propose a randomized masked pilot trial of Zenapax versus placebo. Twenty patients who are 18 years of age or older with Behcet's disease will be randomly assigned to receive either Zenapax or placebo in addition to their standard immunosuppressive therapy. After six months of quiescent disease, patients will be eligible to taper their standard immunosuppressive therapy. The primary purpose of the study is to investigate the safety and efficacy of Zenapax in controlling the recurrent, explosive nature of ocular manifestations in patients with Behcet's disease. Because this study is a Phase I/II study examining both efficacy and safety, primary outcomes for each are defined. The primary safety endpoint is one of the following: a) development of a life threatening complication, namely an exacerbation of systemic or neurological disease, or b) the development of a severe opportunistic infection. The primary efficacy outcomes of this study are based on the number of ocular attacks experienced and the amount of immunosuppressive medications over the 2 year study period, including the ability to taper the standard immunosuppressive therapy. Secondary efficacy outcomes include the level of inflammation as measured by vitreous haze and anterior chamber cells and flare, the presence or absence of cystoid macular edema, the change from baseline in visual acuity, and quality of life issues as measured through questionnaires.
Patients with refractory VF/VT OHCA will be treated with ACLS resuscitation for at least 15 minutes after arrival in the emergency department (ED), or up to 60 minutes from 911 call, after which the physician (MD) can continue resuscitation efforts until ROSC is achieved or futility has been reached based on their clinical judgment. If the patient has not achieved ROSC during the times mentioned above, the ED MD can declare death when he or she believes that ACLS is futile. If ROSC is present upon arrival or has been achieved anytime during resuscitation in the ED, the patient will be taken to the cardiac catheterization laboratory (CCL) for coronary angiography and PCI, and potential VA ECMO or other circulatory support device initiation, as clinically indicated.
Integrating data from virtual voice activated assistants (Amazon Echo Dot with Alexa voice technology), with the rich medical history available in Electronic Health Records (EHR) will allow a truly customized, interactive, and automated personal healthcare assistant. This technology will be validated in patients who have chronic heart failure (HF). Half of the study patients will receive an Amazon Echo Dot (Alexa) enhanced with a HF Care custom Alexa Skill that is patient-specific, or Alexa+. Data on patient interactions with the device will be followed for three months. The control groups will receive standard of care (SOC) HF management. Both study and control groups will receive regular follow up from the HF nurse and data from all hospital or clinic visits will be captured from the EHR.
A method for managing the healthcare of patients. Key characteristics comprising demographic and medical information are identified for a predetermined population, such as a group of employees. Population data substantially conforming to the key characteristics is then gathered for the members. A set of rules, assumptions and algorithms are established using the population data, accepted medical practices and standards, and formularies. Individual member information may then be analyzed using the rules, assumptions and algorithms to provide the member and/or the member's healthcare providers with recommendations regarding the member's medical care. The member's medical outcome is monitored, and further analysis and revised recommendations may be provided if needed. Medical outcome data may also be used to refine the rules, assumptions and algorithms.
<P>PROBLEM TO BE SOLVED: To provide a plaster containing tulbuterol, exhibiting less change with the lapse of time in bonding physical properties such as a skin adhesiveness, etc., after pasting and enabling the constant release of a medicine for a long time and also a high percutaneous absorption even by using a small amount of the medicine to improve medicine utilization rate.  <P>SOLUTION: This plaster is provided by installing an adhesive layer on at least one side surface of a medicine-non-permeating supporting layer, and the adhesive layer is constituted of an acrylic adhesive composition constituted of 76-95 wt. % (meth)acrylic acid alkyl ester copolymer, ≥2.0 wt. % and <5.0 wt. % tulbuterol, 2.0-30 wt. % at least ≥1 kind of a hydrophobic oil selected from the group consisting of squarane, isopropyl palmitate and liquid paraffine and 0-2.0 wt. % at least ≥1 kind of an acidic substance selected from the group consisting of lactic acid, acetic acid and a methacrylic acid copolymer. The (meth)acrylic acid alkyl ester is characterized by consisting of 75-85 wt. % 2-ethylhexyl methacrylate, 10-20 wt. % lauryl methacrylate and 5-15 wt. % 2-ethylhexyl acrylate.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
A method of generating a custom three-dimensional model of a bone is disclosed. A 2D image of the bone is obtained and an orientation and scale of the 2D image are aligned to a pre-determined coordinate system. Based on the 2D image, a representative bone is identified from a library of representative bones that are aligned to the pre-determined coordinate system. Based on the 2D image, an ideal view of a 3D model of the representative bone is selected. Modifications may be made to the 3D model by using additional representative bones from the library. A custom three-dimensional model of the bone is thereby generated.
Eosinophilic gastroenteritis poses a significant diagnostic challenge, particularly in developing countries, where the awareness of this condition may be limited. Here, the case of a patient in her early 30s, who presented with recurrent episodes of abdominal pain and diarrhea, is reported. Initial standard laboratory investigations revealed normal complete blood counts and elevated total serum immunoglobulin E levels. Upper and lower endoscopic evaluations with systemic biopsies did not reveal any significant abnormalities. However, computed tomography revealed a thickened small intestine wall, halo signs, and mild ascites. Analysis of the ascitic fluid confirmed eosinophilia. These findings prompted a diagnosis of eosinophilic gastroenteritis. The patient responded well to a targeted elimination diet, corticosteroids, and antileukotriene medication. The present case emphasizes the importance of considering eosinophilic gastroenteritis in the differential diagnosis of patients who present with abdominal pain and eosinophilic ascites.
Child stunting due to linear growth faltering remains a pervasive issue in low- and middle-income countries. Two schools of thought have existed pertaining to the role of domestic livestock ownership (DLO) in child linear growth. On one hand, it is argued that DLO leads to greater income and financial security, resulting in better child-raising conditions, including greater animal-source food (ASF) consumption, having protective effects towards child stunting. On the other hand, researchers argue that DLO contributes to faecal contamination and transmission of zoonotic enteric infections from animals to children, thus having destructive effects on child growth. Reviews of this association have revealed ambiguous findings. In this perspective, we argue that measuring the association between exposures to domesticated animals and child stunting is difficult and the ambiguous associations revealed are a result of confounding and differences in the management of DLO. We also argue that the increasingly prominent area of research of environmental enteric dysfunction, a sub-clinical condition of the small intestine thought to be due to frequent faecal pathogen exposure and associated with stunting, will be a useful tool to measure the potential destructive effects of DLO on child growth. We present our argument and identify challenges and considerations and directions for future research.
1,246,953. Polymeric sulphonic acids and salts. FARBENFABRIKEN BAYER A.G. 20 Jan., 1970 [29 Jan., 1969], No. 2615/70. Heading C3P. Alkali metal salts of polymeric sulphonic acids and the corresponding acids are made by reacting an alkali metal salt of an aliphatic, cycloaliphatic, araliphatic or aromatic aminomono-sulphonic acid or amino-polysulphonic acid at above 120‹ C. in an aqueous medium with a maleic anhydride homopolymer or a copolymer comprising alternating units derived from (a) maleic anhydride and (b) an olefin, aromatic compound having a carbon-carbon double bond conjugated to an aromatic ring, vinyl ester or vinyl ether, and optionally acidifying and dialysing the resultant alkali metal salt of a polymeric sulphonic acid to form the corresponding acid. The products may be sodium or potassium salts of polymeric sulphonic acids of formula where n is more than 10, R is an alkylene or -CH 2 -CHY- group, where Y is an aryl, acyloxy or alkoxy group, and X is a sulpho-substituted aliphatic, cycloaliphatic, araliphatic or aromatic group.
Patents undergo collection of blood samples before, on day 100, and 1 year after HSCT. Donors undergo collection of blood at the time of HSCT for RNA-based next generation sequencing of TCRA and TCRB genes.
NOT FOR INJECTION INTO THE EYE. Neomycin and Polymyxin B Sulfates, Bacitracin Zinc, and Hydrocortisone Ophthalmic Ointment should never be directly introduced into the anterior chamber of the eye. Ophthalmic ointments may retard corneal wound healing. 

Prolonged use of corticosteroids may result in ocular hypertension and/or glaucoma, with damage to the optic nerve, defects in visual acuity and fields of vision, and in posterior subcapsular cataract formation. 

Prolonged use may suppress the host immune response and thus increase the hazard of secondary ocular infections. Various ocular diseases and long-term use of topical corticosteroids have been known to cause corneal and scleral thinning. Use of topical corticosteroids in the presence of thin corneal or scleral tissue may lead to perforation. 

Acute purulent infections of the eye may be masked or enhanced by the presence of corticosteroid medication. 

If these products are used for 10 days or longer, intraocular pressure should be routinely monitored even though it may be difficult in uncooperative patients. Corticosteroids should be used with caution in the presence of glaucoma. Intraocular pressure should be checked frequently. 

The use of corticosteroids after cataract surgery may delay healing and increase the incidence of filtering blebs. 

Use of the ocular corticosteroids may prolong the course and may exacerbate the severity of many viral infections of the eye (including herpes simplex). Employment of corticosteroid medication in the treatment of herpes simplex requires great caution; frequent slit lamp microscopy is recommended. 

Topical antibiotics, particularly neomycin sulfate, may cause cutaneous sensitization. A precise incidence of hypersensitivity reactions (primarily skin rash) due to topical antibiotics is not known. The manifestations of sensitization to topical antibiotics are usually itching, reddening, and edema of the conjunctiva and eyelid. A sensitization reaction may manifest simply as a failure to heal. During long-term use of topical antibiotic products, periodic examination for such signs is advisable, and the patient should be told to discontinue the product if they are observed. Symptoms usually subside quickly on withdrawing the medication. Applications of products containing these ingredients should be avoided for the patient thereafter (see PRECAUTIONS: General).
This cohort is comprised of individuals that 1) are English-speaking; 2) possess an Android or iOS smartphone; 3) have a diagnosis for anxiety, depression, and/or bipolar disorder; and 4) are active behavioral health patients at any of the four CHCI clinic sites (New London, New Britain, Middletown, or Meriden) where behavioral health providers are using the Ginger.io app with their patients. These patients receive the Ginger.io smartphone application for daily use.
To provide anti-complement factor Bb antibodies and uses thereof.SOLUTION: The present disclosure provides anti-complement factor Bb antibodies, and compositions comprising the antibodies. The anti-Bb antibodies are useful for treating complement-mediated disorders. The present disclosure provides methods of treating complement-mediated disorders. In some cases, the antibodies bind a human complement Bb protein with an affinity of at least 10-8M. In some cases, the antibodies inhibit C3b/Bb-mediated cleavage of C3. In some cases, the antibodies comprise a humanized light-chain framework region. In some cases, the antibodies comprise a humanized heavy-chain framework region. In some cases, the antibodies comprise a humanized light-chain framework region and a humanized heavy-chain framework region.SELECTED DRAWING: Figure 1